Akin to its Breakthrough Therapy program aimed at expediting important new medicines for the general market, the FDA and U.S. Department of Defense (DoD) launch a
joint program to support accelerated approval for products deemed essential for diagnosing, treating or preventing serious or life-threatening disease in military personnel.
Current high-priority DoD programs include freeze-dried plasma, cold-stored platelets and cryopreserved platelets.
The agency will issue a guidance document to assist commercial product developers in identifying opportunities to fill unmet medical needs of the military after holding workshops this year.
And Fred replied as follows:
Good morning .........,
We have indeed established contact with the US Department of Defense. I cannot discuss the specifics at this point in time and yes we are aware of the program.
Thx
Fred
| Frederic Dumais |
| Directeur principal, Communications et relations avec les investisseurs, Senior Director, Communications and Investor Relations |
| |
| 440 Boul. Armand-Frappier |
| Laval, Quebec H7V 4B4 |
+1 450 781 0115
f.dumais@prometic.com |